Peptide directoryBrain, hypothalamus & pituitary

Orexin-B

The second orexin, a straight chain that prefers the OX2 receptor.

Related medicinesSuvorexantLemborexantDaridorexantOveporexton

Where it comes from

Made in
The same lateral hypothalamic neurons as orexin-A, cut from the same precursor
Sent out by
With orexin-A
Acts on
  • Histamine neurons of the tuberomammillary nucleus (OX2R)
  • Other arousal and feeding circuits

What it does

  • Keeps the brain awake through OX2R, the receptor whose loss causes narcolepsy in dogs 1
  • Shorter-lived than orexin-A in blood and spinal fluid
  • Drives feeding and gut motility like orexin-A

In medicine

  • Covered by the orexin medicines: the dual blockers suvorexant, lemborexant and daridorexant switch off both the receptors it uses 3
  • It is not measured in practice. The narcolepsy test reads orexin-A in spinal fluid, because orexin-B breaks down too fast to give a dependable number 1

Beyond the body’s own use

  • The orexin-2 selective agonists for narcolepsy are modelled on its selectivity rather than on orexin-A’s; oveporexton, the first of them, was approved in the United States in 2026 2
  • Nothing containing orexin-B is approved or available outside the laboratory. What is genuinely unsettled is whether the two peptides do different work at all: one gene makes both, so no animal exists that keeps one and loses the other 1

Sources

  1. Sakurai et al., Orexins and orexin receptors, Cell 1998
  2. Dauvilliers et al., Oveporexton for narcolepsy type 1, results from two phase 3 trials, New England Journal of Medicine 2026
  3. Daridorexant (Quviviq), FDA application NDA 214985

This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.